August 2026 Research Update

This month brought one controlled treatment study in PSP with a clear split between a biology signal and a clinical signal. People taking TPN-101 had larger dose-related reductions in a spinal fluid marker linked to nerve cell damage, while measured day-to-day disability (PSP Rating Scale) did not differ from placebo during the same 24-week blinded period. This pattern matters because it suggests the drug may be affecting an underlying process without yet showing a measurable difference in symptoms over the timeframe studied. [1]

Safety looked similar between TPN-101 and placebo in this small Phase 2a study, with the report describing the drug as generally well tolerated and without notable safety differences across doses. The study also included an open-label extension where all participants could receive 400 mg daily, but the provided summary does not describe clinical or biomarker comparisons from that extension. As reported, the most consistent change during the blinded period was the dose-related reduction in cerebrospinal fluid neurofilament light chain (a marker often used to track neurodegeneration in research). [1]

For patients and caregivers, this study mainly adds early research evidence rather than something that changes care right now. It helps clarify that, over 24 weeks, a PSP disability scale may not move even when a lab marker in spinal fluid shifts in the expected direction, which is important for understanding how to interpret early trial news. What remains uncertain is whether the biomarker change will translate into slower symptom worsening over longer follow-up or in larger studies. [1]

Several studies this month focused on a practical problem: telling PSP apart from Parkinson's disease and other parkinsonian conditions. The clearest pattern was that brain imaging and wearable movement measurements found group-level differences that could help classification, while simple blood-based indices were inconsistent or not useful for separating diagnoses. This matters because it points to where researchers are finding stronger signals (brain and movement measures) versus weaker signals (routine blood ratios) for diagnosis support. [2] [3] [4] [5] [6] [7]

On MRI, automated measurement of the pallidum and ventral diencephalon found smaller volumes in PSP than Parkinson's disease in a small cohort, with pallidal volume showing high diagnostic accuracy in that dataset. A separate MRI method that measures brain iron patterns (QSM) reported that PSP had increased iron-related signal mainly in the substantia nigra and pallidum, but that study's diagnostic tests were built to separate healthy people from parkinsonian conditions and Parkinson's disease from MSA-P, not PSP from Parkinson's disease. These are imaging-based research tools, and both reports note the need for confirmation in broader settings, but they add to the picture that PSP has measurable subcortical changes that may help distinguish it. [2] [3]

Wearable sensors during a Timed-Up-and-Go test also separated PSP from Parkinson's disease with high classification performance in a large dataset, and the most informative walking features were clinically recognizable: more time with both feet on the ground, more side-to-side sway, and shorter, slower steps with reduced trunk movement. In contrast, a separate validation study in PSP compared a commercial wearable system against a lab-based motion capture standard and found that only a few core timing measures matched closely, while many spatial and balance-related measures did not. Taken together, these studies suggest wearable measurements can be useful for classification in some settings, but the exact device and metric choice matters, especially as PSP becomes more severe. [4] [8]

Two studies asked whether simple blood-derived indices might help separate diagnoses, and the results were not convincing. A triglyceride-glucose index did not differentiate Parkinson's disease from atypical parkinsonism, and values were similar across PD, MSA, and PSP even though PSP had lower fasting glucose and worse cognitive scores. In a larger comparison of multiple complete-blood-count inflammation ratios, only one (platelet-to-lymphocyte ratio) differed nominally across groups and did not remain significant after multiple-test correction, leaving the overall message as an uncertain trend rather than a reliable separator. [6] [5]

One additional diagnostic study looked at a heart imaging test (123I-mIBG scintigraphy) to separate idiopathic Parkinson's disease from atypical parkinsonism, which included PSP among other conditions. The study reported good overall performance for distinguishing Parkinson's disease from the atypical group using the late heart-to-mediastinum ratio, but it did not present PSP-only accuracy in the provided summary. This adds to the idea that some tests may be better at identifying Parkinson's disease than pinpointing which atypical syndrome a person has. [7]

For patients, these studies mainly add understanding of where diagnosis-support tools are heading rather than changing what testing someone should get now. The strongest research signals this month came from brain imaging measurements and structured walking tests with sensors, which may matter in the future if they are validated across clinics and scanner or device types. What remains uncertain is how well these approaches work for different PSP subtypes and at different disease stages, and whether they can be made consistent enough for routine use. [2] [3] [4] [8] [6] [5] [7]

This month added several pieces to the picture of PSP beyond movement symptoms, combining patient studies and early laboratory work. Across these studies, PSP was described as involving measurable non-motor symptoms (especially REM sleep behavior symptoms), signs of immune activation in blood and spinal fluid in one PSP subtype, and tau-related brain changes that connect to specific brain pathways and protein networks. This matters because it broadens how researchers think about what drives symptoms and how future tests or treatments might be targeted. [9] [10] [11] [12] [13] [14]

A large symptom-focused study found probable REM sleep behavior disorder (acting out dreams) in about 1 in 5 people with PSP and in none of the matched controls. People with these sleep symptoms also had a higher burden of other non-motor problems and poorer quality of life, and attention or memory problems and gastrointestinal symptoms were reported as independent predictors of probable REM sleep behavior disorder within PSP. This adds a clearer signal that sleep-related symptoms can be part of PSP and may cluster with other day-to-day non-motor difficulties. [9]

One case-control study in the PSP-S subtype reported higher levels of several inflammatory signals in blood and spinal fluid compared with controls, along with increased neuroinflammation on PET-MRI in a small imaging subset. The same study reported that plasma IL-1beta correlated with spinal fluid IL-1beta and with disease severity, although many marker-severity links did not hold after correcting for multiple comparisons. This provides an early, connected picture across blood, spinal fluid, and brain imaging that inflammation-related pathways may be active in at least one PSP presentation, while also showing that not every measured marker cleanly tracks symptoms. [10]

Imaging and brain-tissue studies added detail about where tau pathology concentrates and what it may interact with. A tau PET and white matter study found PSP had mainly subcortical and brainstem tau signal with involvement of the dentatorubrothalamic tract, and the tract measures were linked to motor impairment in PSP. Separately, analysis of human brain tissue reported that PSP tau aggregates were connected to a distinct set of interacting proteins, described as showing interactor depletion with selective proteasome enrichment compared with other diseases, supporting the idea that tau may behave differently across disorders. [11] [12]

Two additional studies highlighted astrocyte-related signals, from different angles. A modeling study across the broader FTLD spectrum (including PSP) suggested that a blood marker linked to astrocyte activation (GFAP) could be among the earliest changes in the overall disease cascade, before later clinical decline measures in that framework. In a transgenic mouse model designed to mimic PSP-like astrocytic tau, astrocyte 4R tau disrupted Aquaporin-4 positioning, impaired brain fluid exchange, reduced dopamine and acetylcholine, and was linked to motor and thinking problems in mice, offering one possible chain of events to test in future work. [13] [14]

For patients and caregivers, these studies mostly add understanding of PSP rather than immediate changes in diagnosis or treatment. The sleep study suggests that dream-enactment symptoms can be part of PSP and may come alongside other non-motor issues that affect quality of life, which may matter now for recognizing the full symptom picture. The inflammation and tau-biology findings are earlier-stage signals that may matter later if they lead to reliable tests or targeted treatments, but it is still uncertain how consistent these signals are across all PSP subtypes and stages. [9] [10] [11] [12] [13] [14]